Trial Profile
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs INCB 086550 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 28 Nov 2023 Status changed from active, no longer recruiting to completed.
- 01 Nov 2023 Planned End Date changed from 1 Feb 2024 to 15 Nov 2023.
- 01 Nov 2023 Planned primary completion date changed from 29 Sep 2023 to 15 Nov 2023.